CD276 and Nijmegen breakage syndrome: Currently, our GPC2-targeting CAR CT3 is being planned for clinical trial (16), and 6 open CAR T cell clinical trials against CD276+ solid tumors including NBs are ongoing (Supplemental Table 1).